Inventor · disambiguated record
Karl-Heinz Eisele
Also filed as: EISELE KARL-HEINZ
11 granted patents·7 pending applications·36 citations·filing 2008–2023
86Inventor score
Top patents by PatentIndex Score
18 records- 0188US10725025B2Methods for enhancing the specific uptake of botulinum neurotoxins into cellsMERZ PHARMA GMBH & CO KGAA·Filed 2016·Granted Jul 28, 2020·5 cites·25 claims
- 0282US9447175B2Means and methods for manufacturing highly pure neurotoxinPFEIL MICHAEL·Filed 2010·Granted Sep 20, 2016·10 cites·5 claims
- 0381US9314514B2Modified neurotoxins with poly-glycine and uses thereofMERZ PHARMA GMBH & CO KGAA·Filed 2012·Granted Apr 19, 2016·6 cites·12 claims
- 0480US10781421B2Cellular test systems for the determination of the biological activities of neurotoxin polypeptidesMERZ PHARMA GMBH & CO KGAA·Filed 2018·Granted Sep 22, 2020·2 cites·13 claims
- 0580US10125350B2Cellular test systems for the determination of the biological activities of neurotoxin polypeptidesMERZ PHARMA GMBH & CO KGAA·Filed 2013·Granted Nov 13, 2018·4 cites·12 claims
- 0677US9310386B2In vitro assay for quantifying clostridial neurotoxin activityWILK THOMAS·Filed 2011·Granted Apr 12, 2016·6 cites·14 claims
- 0777US8841080B2System for determining unprocessed and partially processed neurotoxin type ATAYLOR HAROLD VICTOR·Filed 2010·Granted Sep 23, 2014·3 cites·11 claims
- 0868US2009010965A1Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxinMERZ PHARMA GMBH & CO KGAA·Filed 2008·Application pending·0 cites
- 0964US2025152682A1Liquid botulinum toxin formulation and use thereofMERZ PHARMA GMBH & CO KGAA·Filed 2023·Application pending·0 cites
- 1064US2025161186A1Liquid botulinum toxin formulation and use thereofMERZ PHARMA GMBH & CO KGAA·Filed 2023·Application pending·0 cites
- 1158US9213026B2System for determining unprocessed and partially processed neurotoxin type AMERZ PHARMA GMBH & CO KGAA·Filed 2014·Granted Dec 15, 2015·0 cites·3 claims
- 1249US9963502B2Antibody that specifically binds partially processed or unprocessed neurotoxin polypeptidesMERZ PHARMA GMBH & CO KGAA·Filed 2016·Granted May 8, 2018·0 cites·2 claims
- 1346US10634683B2Methods for the determination of the biological activities of neurotoxin polypeptidesMERZ PHARMA GMBH & CO KGAA·Filed 2015·Granted Apr 28, 2020·0 cites·14 claims
- 1445US2016289731A1Means and methods for determination of botulinum neurotoxin biological activityMERZ PHARMA GMBH & CO KGAA·Filed 2013·Application pending·0 cites
- 1544US2015044709A1Means and methods for determining neurotoxin activity based on a modified luciferaseMERZ PHARMA GMBH & CO KGAA·Filed 2013·Application pending·0 cites
- 1642US10921312B2Gangliosides for standardizing and increasing the sensitivity of cells to botulinum neurotoxins in in vitro test systemsMERZ PHARMA GMBH & CO KGAA·Filed 2015·Granted Feb 16, 2021·0 cites·10 claims
- 1738US2013158235A1Selective manufacture of recombinant neurotoxin polypeptidesGREIN SWEN·Filed 2011·Application pending·0 cites
- 1837US2012282647A1Assay for quantifying clostridial neurotoxinMANDER GERD J·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Karl-Heinz Eisele files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →